TCM
IBB icon

Traynor Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Traynor Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.15M Buy
13,287
+1,654
+14% +$283K 0.13% 85
2025
Q4 		$1.96M Buy
11,633
+355
+3% +$57.7K 0.1% 89
2025
Q3 		$1.63M Sell
11,278
-4,597
-29% -$627K 0.09% 91
2025
Q2 		$2.03M Sell
15,875
-5,977
-27% -$734K 0.14% 68
2025
Q1 		$2.79M Sell
21,852
-1,107
-5% -$150K 0.24% 61
2024
Q4 		$3.04M Sell
22,959
-2,045
-8% -$287K 0.2% 66
2024
Q3 		$3.64M Buy
25,004
+2,525
+11% +$365K 0.22% 62
2024
Q2 		$3.09M Buy
22,479
+972
+5% +$130K 0.23% 60
2024
Q1 		$2.95M Buy
21,507
+2,294
+12% +$313K 0.26% 60
2023
Q4 		$2.61M Sell
19,213
-1,009
-5% -$123K 0.27% 57
2023
Q3 		$2.47M Buy
20,222
+1,102
+6% +$140K 0.31% 55
2023
Q2 		$2.43M Buy
19,120
+492
+3% +$63.9K 0.3% 54
2023
Q1 		$2.41M Buy
18,628
+2
+0% +$262 0.35% 49
2022
Q4 		$2.45M Buy
18,626
+1,396
+8% +$180K 0.34% 49
2022
Q3 		$2.02M Sell
17,230
-1,473
-8% -$183K 0.36% 46
2022
Q2 		$2.2M Sell
18,703
-13,361
-42% -$1.59M 0.38% 48
2022
Q1 		$4.18M Sell
32,064
-5,534
-15% -$721K 0.54% 41
2021
Q4 		$5.74M Sell
37,598
-550
-1% -$85.2K 0.68% 32
2021
Q3 		$6.17M Sell
38,148
-287
-0.7% -$48.3K 0.84% 26
2021
Q2 		$6.33M Buy
38,435
+2,132
+6% +$328K 0.88% 25
2021
Q1 		$5.46M Buy
36,303
+2,443
+7% +$388K 0.9% 26
2020
Q4 		$5.13M Sell
33,860
-2,353
-6% -$336K 0.91% 26
2020
Q3 		$4.94M Buy
36,213
+1,499
+4% +$203K 1.13% 21
2020
Q2 		$4.75M Buy
34,714
+16,438
+90% +$2.1M 1.14% 18
2020
Q1 		$1.97M Buy
18,276
+4,939
+37% +$569K 0.7% 34
2019
Q4 		$1.61M Sell
13,337
-581
-4% -$64.8K 0.43% 52
2019
Q3 		$1.38M Sell
13,918
-623
-4% -$65.2K 0.43% 49
2019
Q2 		$1.59M Buy
14,541
+29
+0.2% +$3.08K 0.52% 43
2019
Q1 		$1.62M Buy
14,512
+544
+4% +$59.7K 0.54% 39
2018
Q4 		$1.35M Sell
13,968
-258
-2% -$27.4K 0.56% 35
2018
Q3 		$1.73M Buy
14,226
+571
+4% +$67.2K 0.56% 37
2018
Q2 		$1.51M Buy
13,655
+1,195
+10% +$128K 0.55% 35
2018
Q1 		$1.33M Buy
12,460
+929
+8% +$103K 0.54% 36
2017
Q4 		$1.23M Buy
11,531
+1,496
+15% +$160K 0.53% 42
2017
Q3 		$1.11M Sell
10,035
-1,089
-10% -$116K 0.53% 43
2017
Q2 		$1.18M Buy
11,124
+855
+8% +$84.2K 0.58% 37
2017
Q1 		$1.02M Buy
10,269
+903
+10% +$86.4K 0.57% 35
2016
Q4 		$844K Buy
9,366
+642
+7% +$58.4K 0.56% 40
2016
Q3 		$777K Buy
8,724
+1,218
+16% +$116K 0.55% 42
2016
Q2 		$650K Sell
7,506
-879
-10% -$78.9K 0.51% 44
2016
Q1 		$729K Sell
8,385
-1,113
-12% -$99.5K 0.58% 40
2015
Q4 		$1.07M Buy
9,498
+1,425
+18% +$155K 0.77% 32
2015
Q3 		$816K Buy
8,073
+459
+6% +$55.1K 0.7% 31
2015
Q2 		$936K Buy
7,614
+228
+3% +$27.3K 0.78% 27
2015
Q1 		$845K Buy
7,386
+546
+8% +$60.2K 0.81% 24
2014
Q4 		$691K Buy
+6,840
New +$665K 0.8% 22

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Traynor Capital Management's IBB Position: Q1 2026 in Review

Traynor Capital Management increased its iShares Biotechnology ETF (IBB) stake by 14% in Q1 2026, buying an estimated $283K and bringing the position to 13,287 shares worth $2.15M. The position accounts for 0.13% of the portfolio, ranked #85.

Traynor Capital Management first reported a position in IBB in Q4 2014 and has held it in 46 quarters since. The position peaked at $6.33M in Q2 2021. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Traynor Capital Management held 13,287 shares of iShares Biotechnology ETF worth $2.15M as of Q1 2026.
  • Traynor Capital Management bought 1,654 iShares Biotechnology ETF shares in Q1 2026, an estimated $283K.
  • iShares Biotechnology ETF made up 0.13% of Traynor Capital Management's portfolio in Q1 2026, its #85 holding.
  • Traynor Capital Management first reported a position in iShares Biotechnology ETF in Q4 2014 and has held it in 46 quarters since.
  • Traynor Capital Management's iShares Biotechnology ETF position peaked at $6.33M in Q2 2021.
  • 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Traynor Capital Management's 13F filing for Q1 2026, filed 15 May 2026.